NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization834.81 mln
Float14.85 mln
Earnings Date11/10/2026
EPS
16.89
Robust
P / E
2.67
Deeply undervalued
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
1.6
Highly suspicious
1-Year Forecast
63.00
Strong upside
Relative Strength
88
/ 100
Strongly outperforming
Business Description
Rigel Pharmaceuticals is a US-based biotech company focused on developing treatments for blood disorders and cancer. Its portfolio includes three approved drugs ? TAVALISSE, REZLIDHIA, and GAVRETO ? targeting conditions such as chronic low platelet counts, a form of leukemia, and certain thyroid and lung cancers. The company is also advancing a new oral drug, R289, through early clinical trials for a range of blood, immune, and inflammatory conditions. Founded in 1996 and based in South San Francisco, Rigel works with leading research institutions, including MD Anderson Cancer Center, to expand the use of its treatments across additional cancer types.
